{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T06:46:49Z","timestamp":1767163609455,"version":"build-2238731810"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1124\/jpet.119.263178","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T13:54:27Z","timestamp":1582638867000},"page":"184-192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["A Mechanistic and Translational Pharmacokinetic-Pharmacodynamic Model of Abicipar Pegol and Vascular Endothelial Growth Factor Inhibition"],"prefix":"10.1016","volume":"373","author":[{"given":"Kenneth T.","family":"Luu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer R.","family":"Seal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayssa","family":"Attar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.119.263178_bib1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ajo.2010.04.011","article-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2","volume":"150","author":"Abraham","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1124\/jpet.119.263178_bib2","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0002-9394(14)75794-0","article-title":"Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy","volume":"118","author":"Adamis","year":"1994","journal-title":"Am J Ophthalmol"},{"key":"10.1124\/jpet.119.263178_bib3","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders","volume":"331","author":"Aiello","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.119.263178_bib4","series-title":"Age-Related Macular Degeneration","year":"2015"},{"key":"10.1124\/jpet.119.263178_bib5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.exer.2003.10.013","article-title":"Pigment epithelium-derived factor in the monkey retinal pigment epithelium and interphotoreceptor matrix: apical secretion and distribution","volume":"78","author":"Becerra","year":"2004","journal-title":"Exp Eye Res"},{"issue":"10 Suppl","key":"10.1124\/jpet.119.263178_bib6","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ophtha.2009.06.045","article-title":"Introduction: understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration","volume":"116","author":"Bressler","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1124\/jpet.119.263178_bib7","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/IAE.0000000000000717","article-title":"Societal costs associated with neovascular age-related macular degeneration in the United States","volume":"36","author":"Brown","year":"2016","journal-title":"Retina"},{"key":"10.1124\/jpet.119.263178_bib8","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s001250050794","article-title":"Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathy","volume":"40","author":"Burgos","year":"1997","journal-title":"Diabetologia"},{"key":"10.1124\/jpet.119.263178_bib9","doi-asserted-by":"crossref","DOI":"10.1089\/jop.2018.0062","article-title":"Double-masked, randomized, phase 2 evaluation of abicipar pegol (an anti-VEGF DARPin therapeutic) in neovascular age-related macular degeneration","author":"Callanan","year":"2018","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1124\/jpet.119.263178_bib10","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ajo.2012.09.032","article-title":"Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I\/II study","volume":"155","author":"Campochiaro","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1124\/jpet.119.263178_bib11","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1089\/jop.2011.0099","article-title":"The effects and underlying mechanisms of S-allyl l-cysteine treatment of the retina after ischemia\/reperfusion","volume":"28","author":"Chen","year":"2012","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1124\/jpet.119.263178_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.exer.2015.05.003","article-title":"Rabbit as an animal model for intravitreal pharmacokinetics: clinical predictability and quality of the published data","volume":"137","author":"Del Amo","year":"2015","journal-title":"Exp Eye Res"},{"key":"10.1124\/jpet.119.263178_bib13","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","article-title":"Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial","volume":"124","author":"Dugel","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1124\/jpet.119.263178_bib14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1124\/jpet.119.263178_bib15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0006-8993(02)03766-6","article-title":"Immunocytochemical localization of vascular endothelial growth factor in neurons and glial cells of human retina","volume":"969","author":"Famiglietti","year":"2003","journal-title":"Brain Res"},{"key":"10.1124\/jpet.119.263178_bib16","first-page":"58","article-title":"Blood flow in the normal human retina","volume":"30","author":"Feke","year":"1989","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1124\/jpet.119.263178_bib17","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1001\/archopht.1984.01040031330019","article-title":"Age-related macular degeneration and blindness due to neovascular maculopathy","volume":"102","author":"Ferris","year":"1984","journal-title":"Arch Ophthalmol"},{"key":"10.1124\/jpet.119.263178_bib18","doi-asserted-by":"crossref","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","article-title":"Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis","volume":"5","author":"Flaxman","year":"2017","journal-title":"Lancet Glob Health"},{"key":"10.1124\/jpet.119.263178_bib19","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1586\/eop.12.34","article-title":"Vitreomacular interface diseases: pathophysiology, diagnosis and future treatment options","volume":"7","author":"Girach","year":"2014","journal-title":"Expert Rev Ophthalmol"},{"key":"10.1124\/jpet.119.263178_bib20","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.119.263178_bib21","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration [published correction appears in Ophthalmology (2013) 120:209\u2013210]","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1124\/jpet.119.263178_bib22","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ajo.2013.12.018","article-title":"Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration","volume":"157","author":"Holekamp","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1124\/jpet.119.263178_bib23","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/bjo.81.2.154","article-title":"Increased expression of angiogenic growth factors in age-related maculopathy","volume":"81","author":"Kliffen","year":"1997","journal-title":"Br J Ophthalmol"},{"key":"10.1124\/jpet.119.263178_bib24","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1167\/iovs.09-3582","article-title":"Vitreous VEGF clearance is increased after vitrectomy","volume":"51","author":"Lee","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1124\/jpet.119.263178_bib25","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1124\/jpet.112.191999","article-title":"A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition","volume":"341","author":"Luu","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.263178_bib26","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1124\/jpet.103.049502","article-title":"Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta1a in monkeys","volume":"306","author":"Mager","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.263178_bib27","first-page":"574","article-title":"Vascular endothelial growth factor\/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model","volume":"145","author":"Miller","year":"1994","journal-title":"Am J Pathol"},{"key":"10.1124\/jpet.119.263178_bib28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/08820530902800017","article-title":"Review of the ocular angiogenesis animal models","volume":"24","author":"Montezuma","year":"2009","journal-title":"Semin Ophthalmol"},{"key":"10.1124\/jpet.119.263178_bib29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis"},{"key":"10.1124\/jpet.119.263178_bib30","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1146\/annurev-pharmtox-010611-134654","article-title":"Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy","volume":"55","author":"Pl\u00fcckthun","year":"2015","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/jpet.119.263178_bib31","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ajo.2015.06.023","article-title":"Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study","volume":"160","author":"Prenner","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1124\/jpet.119.263178_bib32","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1167\/iovs.18-25307","article-title":"Functional characterization of abicipar-pegol, an anti-VEGF DARPin therapeutic that potently inhibits angiogenesis and vascular permeability","volume":"59","author":"Rodrigues","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1124\/jpet.119.263178_bib33","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","article-title":"Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)","volume":"98","author":"Schmidt-Erfurth","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1124\/jpet.119.263178_bib34","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ophtha.2010.09.004","article-title":"Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study","volume":"118","author":"Schmidt-Erfurth","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1124\/jpet.119.263178_bib35","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.ophtha.2011.12.016","article-title":"HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration","volume":"119","author":"Singer","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1124\/jpet.119.263178_bib36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2174\/1871523016666170502115816","article-title":"Designed ankyrin repeat proteins: a look at their evolving use in medicine with a focus on the treatment of chorioretinal vascular disorders","volume":"16","author":"Smithwick","year":"2017","journal-title":"Antiinflamm Antiallergy Agents Med Chem"},{"key":"10.1124\/jpet.119.263178_bib37","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.ajo.2014.05.037","article-title":"Treatment of exudative age-related macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I\/II study","volume":"158","author":"Souied","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1124\/jpet.119.263178_bib38","series-title":"The European Association for Vision and Eye Research (EVER); 2014 Oct 1\u20134; Nice, France","article-title":"Comparison of ocular tissue weights (volumes) and tissue collection techniques in commonly used preclinical animal species","author":"Struble","year":"2014"},{"key":"10.1124\/jpet.119.263178_bib39","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1444-0938.2002.tb02384.x","article-title":"The mechanism of aqueous humour formation","volume":"85","author":"To","year":"2002","journal-title":"Clin Exp Optom"},{"key":"10.1124\/jpet.119.263178_bib40","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ajo.2005.10.012","article-title":"Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization","volume":"141","author":"Tong","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1124\/jpet.119.263178_bib41","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000264414","article-title":"Determination of the wet and dry weight of iris, ciliary body and choroid in man and in different animal species","volume":"1","author":"Wu","year":"1970","journal-title":"Ophthalmic Res"},{"key":"10.1124\/jpet.119.263178_bib42","doi-asserted-by":"crossref","first-page":"a017178","DOI":"10.1101\/cshperspect.a017178","article-title":"Clinical characteristics and current treatment of age-related macular degeneration","volume":"5","author":"Yonekawa","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1124\/jpet.119.263178_bib43","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2174\/1871527315666151110124957","article-title":"Rabbit models of ocular diseases: new relevance for classical approaches","volume":"15","author":"Zernii","year":"2016","journal-title":"CNS Neurol Disord Drug Targets"}],"updated-by":[{"DOI":"10.1124\/jpet.120.000210","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000}}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524258705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524258705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.119.263178","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T08:56:02Z","timestamp":1739955362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524258705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0022356524258705"],"URL":"https:\/\/doi.org\/10.1124\/jpet.119.263178","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Mechanistic and Translational Pharmacokinetic-Pharmacodynamic Model of Abicipar Pegol and Vascular Endothelial Growth Factor Inhibition","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.119.263178","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by The Author(s)","name":"copyright","label":"Copyright"}]}}